IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC) Meeting Abstract
| Authors: | Motzer, R. J.; Powles, T.; Atkins, M. B.; Escudier, B.; McDermott, D. F.; Suarez, C.; Bracarda, S.; Stadler, W. M.; Donskov, F.; Lee, J. L.; Hawkins, R. E.; Ravaud, A.; Alekseev, B. Y.; Staehler, M. D.; Uemura, M.; Donaldson, F.; Li, S.; Huseni, M. A.; Schiff, C.; Rini, B. I. |
| Abstract Title: | IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC) |
| Meeting Title: | 2018 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2018 Feb 8-10 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-02-20 |
| Language: | English |
| ACCESSION: | WOS:000436179500571 |
| DOI: | 10.1200/JCO.2018.36.6_suppl.578 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 578 -- Source: Wos |
